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ABSTRACT 1 
An alternative to liver transplantation for patients with liver failure remains an unmet need.  In 2 
acute liver failure, the ideal extracorporeal liver support device would replace the functions of 3 
the failing liver in order to permit spontaneous recovery, given the incredible regenerative 4 
potential of the liver, negating the need for transplantation. In acute-on-chronic liver failure, 5 
an extracorporeal liver support device would ideally support hepatic function until recovery to 6 
liver function prior to acute decompensation or until liver transplantation.  In decompensated 7 
cirrhosis, an extracorporeal liver support device could again be used to support hepatic 8 
function until transplant. In addition, extracorporeal liver support devices may have potential 9 
to treat the multi-organ failure that accompanies liver failure including hepatic 10 
encephalopathy, renal failure and immune dysfunction or indeed potential to promote liver 11 
regeneration. Creation of an extracorporeal bioartificial liver able to completely replace liver 12 
function remains an unmet need. This review will describe a number of technologies suitable 13 
for clinical trials in man, which have resulted from decades of engineering and biological 14 
research to develop a bioreactor able to adequately sustain functional hepatocytes. In 15 
addition, this review will describe artificial liver support devices, primarily designed to replace 16 
the detoxifying functions of the liver and consider the current data available or studies 17 
required to support their use in liver failure patients on the transplant waiting list. 18 
 19 
INTRODUCTION 20 
Mortality in patients with liver failure who cannot be rescued with liver transplantation 21 
remains high despite improvements in supportive care (1). The fundamental thinking behind 22 
the use of extracorporeal liver support devices (ELSD) is the idea that if the patient’s liver 23 
and extrahepatic organs can be supported long enough, recovery should be possible, 24 
because of the regeneration potential of the liver (2). Alternative aims of ELSD may be to 25 
‘bridge’ liver failure patients to liver transplantation or to support patients with end-stage liver 26 
disease while on the waiting list for transplantation. Additional therapeutic goals may be to 27 
treat end organ dysfunction such as hepatic encephalopathy (HE), renal failure or immune 28 
 4 
 
dysfunction (3). Finally, as one understands the pathophysiological basis of regeneration or 1 
its inhibition better, ELSD may be used to target particular molecules to enhance this 2 
regenerative process. Depending upon whether the liver failure occurs on the background of 3 
a previously healthy liver or in patients with underlying chronic liver disease, the conditions 4 
are referred to as acute liver failure (ALF) or acute-on-chronic liver failure (ACLF) 5 
respectively (Table 1).  6 
 7 
ALF is a rare disease and is defined as the occurrence of HE in patients with severe acute 8 
liver injury within 6-months of the onset of symptoms (4). From a pathophysiological 9 
perspective, patients with ALF are the perfect group of patients likely to benefit from ELSD 10 
because recovery is likely to return the patient to their pre-liver failure state, in which there is 11 
no pre-existing liver pathology. It is becoming clear that in addition to providing support for 12 
hepatic function, modulation of hepatic and systemic inflammation will be important to 13 
prevent deaths either from an exaggerated inflammatory response or infection (3). 14 
 15 
ACLF is much more common than ALF and typically occurs in patients with cirrhosis (5). The 16 
condition is characterized by acute deterioration of a cirrhotic patient with or without a 17 
recognized precipitating event, associated with organ failures and high mortality rates (6). 18 
Data from prospective studies are now available that allow accurate, sequential 19 
assessments of patients, which provide prognostic information. The CLIF Consortium organ 20 
failure score is used for diagnosis of the syndrome (Table 2) and the CLIF Consortium ACLF 21 
score for defining the prognosis (7). A pre-ACLF group has now been identified, which will 22 
allow studies of ELSD to prevent the occurrence of ACLF in susceptible patients (8). 23 
Systemic inflammation is the key pathophysiological factor that drives the syndrome making 24 
this a particular target of ELSDs (9). The aim of ELSDs in patients with ACLF is to support 25 
hepatic function during acute decompensation until recovery to baseline liver function and/or 26 
liver transplantation.  27 
 28 
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Decompensated cirrhosis is pathophysiologically different and typically represents patients 1 
that have end-stage cirrhosis with varying degrees of end-organ dysfunction. In this group of 2 
patients, ELSD is aimed at supporting them until liver transplantation. 3 
 4 
This review describes the state of the art about the types of ELSDs that are available, the 5 
results of the large and important clinical trials and the new ELSDs that are in or about to 6 
enter clinical trials. The reported human, randomised, controlled, clinical trials of ELSDs, for 7 
which survival was the primary outcome, are given in Table 3 with selected survival data 8 
shown in Figures 1 to 3. 9 
 10 
CURRENTLY AVAILABLE EXTRACORPOREAL LIVER SUPPORT DEVICES 11 
The currently available artificial ELSDs are based on the principal of removal of protein 12 
bound and water soluble substances (blood purification) by albumin dialysis, by plasma 13 
separation and filtration or by therapeutic plasma exchange. Devices based solely on the 14 
removal of water soluble substances (blood detoxification) have not shown any benefit in 15 
survival, possibly because of the limited, non-specific absorptive capacity of chemical 16 
adsorbents (10). 17 
 18 
The following artificial ELSDs are currently available:  19 
(i) The Molecular Adsorbents Recirculating System (MARS®, Gambro, Sweden) was 20 
first described in 1993 (Supplementary Material Figure S1) (11). In MARS®, blood 21 
is dialyzed across an albumin-impermeable, approximately 50-60 kDa cut-off, 22 
membrane against 20% human serum albumin (HSA).  HSA solution is 23 
continuously stripped of protein bound and water soluble toxins by passage 24 
through a secondary circuit containing a charcoal column, an anion exchange 25 
resin column and a low-flux dialyzer (12-14).  26 
(ii) The Fractionated Plasma Separation, Adsorption and Dialysis device 27 
(Prometheus®, Fresenius Medical Care, Germany) separates the patient’s 28 
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albumin/plasma from blood by passage across an approximately 300 kDa cut-off 1 
membrane (Supplementary Material Figure S2).  Patient albumin/plasma is then 2 
passed directly over two columns containing different adsorbents. A high-flux 3 
dialyzer inserted into the blood circuit clears water-soluble substances (15, 16).  4 
(iii) Single pass albumin dialysis® (SPAD®) can be carried out with a standard dialysis 5 
setup, by use of hollow fibres made of a high-flux albumin-impermeable 6 
membrane and the addition of HSA to the dialysis solution to enable solute 7 
transfer from the patient's blood to the dialysis solution (Supplementary Material 8 
Figure S3)  (17, 18). 9 
(iv) Therapeutic plasma exchange (TPE) involves extracorporeal separation and 10 
removal of patient plasma from blood and return of blood cells with a replacement 11 
fluid to the patient. Fresh frozen plasma is the typical replacement fluid, but HSA 12 
has also been reported (19). 13 
 14 
MARS®, Prometheus® and SPAD® are all able to reduce serum bilirubin and bile acids. 15 
Studies comparing MARS® and Prometheus® in ACLF show higher efficiency of 16 
Prometheus® for removal of bilirubin and urea and equal efficiency for removal of bile acids 17 
(20, 21). However, an actual improvement of synthetic liver function has neither been 18 
expected nor observed. For patients awaiting liver transplantation improvement of systemic 19 
haemodynamics, renal function or HE might be able to “buy” valuable time until an organ 20 
becomes available, serve as a bridge to recovery and it can be hypothesized that this would 21 
also impact on prognosis after transplantation.  22 
 23 
Molecular Adsorbents Recirculating System®  24 
A meta-analysis (22) of 4 randomized (14, 23-25) and 2 selected non-randomized trials (26, 25 
27) did not show any overall effect of MARS® on mortality. However, explorative analysis of 26 
the 2 non-randomized trials revealed a significant reduction in mortality in the MARS® group 27 
as compared to the standard medical treatment (SMT) group (22). Another randomized 28 
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controlled trial showed that MARS® therapy in patients with ACLF has a beneficial effect on 1 
circulating neurohormones, nitric oxide and free radical production, and reduces markers of 2 
oxidative stress (28). The clinical effects of these changes are reflected in individual organ 3 
function with temporal improvement in cholestasis, liver function, renal function, 4 
encephalopathy, and in some patients, mean arterial pressure (28). Indeed, one of the most 5 
consistent findings in studies of MARS® in ACLF is an improvement in portal and systemic 6 
haemodynamics (29-31).  Furthermore a large randomized controlled trial revealed a 7 
significant effect of MARS® on the severity of HE (32). The largest study so far – the RELIEF 8 
trial – however could not show a benefit of MARS® on mortality in ACLF, but demonstrated 9 
safety, a dialysis effect and a modest effect on HE (33) (Figure 1, Table 3). Failure to show a 10 
survival benefit may have been due to the heterogeneous patient population.  However, 11 
another large, randomized study in ALF – the FULMAR trial – also failed to show a survival 12 
benefit of MARS® (Table 3). In this study most patients were transplanted within a median of 13 
16.2 hours, leaving little time for a liver support system to demonstrate its effect (34). A 14 
retrospective study of continuous MARS® treatment in critically ill patients listed for liver 15 
transplantation with ALF, ACLF or graft dysfunction, showed that MARS® may be of value as 16 
a bridge to transplant but also revealed severe side effects with respect to coagulation and 17 
electrolytes (35). Therefore, the use of MARS® in patients with liver failure waiting for an 18 
organ should be performed under close observation with treatment of coagulopathy and 19 
electrolyte disturbances (35). In another single centre observation from the Netherlands that 20 
included 20 children with ALF or graft dysfunction, MARS® could be successfully applied, but 21 
with similar coagulation side effects and the need for liver transplantation was not reduced 22 
(36). Another single centre experience from Mexico suggested that MARS® reduced the 23 
need for liver transplantation by contributing to native liver recovery (37). However, a 24 
retrospective cohort study is not the optimal study design to answer this question.  25 
 26 
From the available data, it is not possible to conclude whether or not MARS® is beneficial for 27 
patients on the transplant waiting list. It is possible that efficiency of the device is not optimal. 28 
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Therefore, the development of a device with higher efficiency might be of value. Recently, 1 
the use of a double absorption unit in parallel has been tested (38). 2 
 3 
Prometheus® 4 
Initial and subsequent uncontrolled data for Prometheus® show high elimination of albumin 5 
bound toxins and good safety data (16, 39). Comparable to MARS®, Prometheus® can be 6 
used safely in patients awaiting an urgent liver transplantation (40), but severe coagulation 7 
disturbances have been reported (41). The largest cohort study of Prometheus® in ALF 8 
patients was performed in Turkey and demonstrated safety and efficacy: one third of patients 9 
survived without transplantation, leading the authors to suggest that Prometheus® may be 10 
effective as a bridge to recovery (42). However, as for MARS®, Prometheus® failed to 11 
improve survival of patients with ACLF in a large prospective randomized study (Figure 2, 12 
Table 3) (43). Therefore the current data does not allow us to conclude whether or not 13 
Prometheus® is of benefit to patients on the waiting list.  14 
 15 
Single pass albumin dialysis® 16 
SPAD® can be used with any dialysis setup, therefore there is no need to invest in an extra 17 
machine.  However, the amount of HSA required is high. SPAD® has been mainly tested in 18 
vitro and reported in case reports. In vitro there is evidence that the detoxification capacity of 19 
SPAD® is greater than MARS®(18). In a retrospective study, MARS® and SPAD® showed 20 
equal efficacy (44). In ALF, SPAD® was well tolerated but failed to improve survival and did 21 
not change referral to liver transplantation (45). In a single-center experience from Germany, 22 
SPAD® did not have any impact on survival or transplantation rate in patients with ACLF 23 
listed for transplantation (46). However, patient numbers were small. Again, it is not possible 24 
to conclude whether or not SPAD® is beneficial for patients on the waiting list. 25 
 26 
Therapeutic plasma exchange 27 
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Therapeutic plasma exchange has been reported in isolated ALF and ACLF patients since 1 
the 1960s. Rationale has been removal of all toxins, as well as harmful inflammatory 2 
mediators and replacement of beneficial plasma proteins normally synthesised by the liver. 3 
In liver failure, TPE has been shown to reduce serum bilirubin and ammonia and to increase 4 
coagulation factors improving coagulopathy. Hypocalcaemia and alkalosis occur due to 5 
anticoagulant use, but are easily corrected (19). A recent multi-centre open randomised 6 
controlled trial of high-volume TPE (HVP, exchange of approximately 8-12 litres or 15% body 7 
weight of plasma), on three consecutive days, in 182 ALF patients demonstrated increased 8 
survival to hospital discharge  (Figure 3, Table 3) (47). In patients who fulfilled poor 9 
prognostic criteria, but were not listed for transplant, HVP (n=28) increased survival 10 
compared to SMT (n=36). This survival advantage was associated with immune modulation 11 
and improvement in renal function, cardiovascular status, SOFA score and CLIF-SOFA 12 
score (47). 13 
 14 
EMERGING TECHNOLOGIES IN EXTRACORPOREAL LIVER SUPPORT DEVICES  15 
Bioartificial ELSDs include a bioreactor that contains hepatocytes, which in the most ideal 16 
scenario, would replace the functions of the failing liver including: ammonia detoxification via 17 
the urea cycle; drug metabolism; protein synthesis; and carbohydrate and lipid metabolism 18 
(48). Bioartificial ELSD development has been limited by their requirement for primary 19 
hepatocytes, which demonstrate better hepatocyte functionality compared to immortalised 20 
cell lines, but with the accompanying disadvantage of reduced cell viability and limited 21 
availability (48). Moreover, bioreactor design has been challenged with maintaining large 22 
hepatocyte cultures for effective patient treatment, whilst simultaneously acting as an 23 
effective interface between bioreactor hepatocyte function and patient plasma (48). 24 
Nevertheless progressive evolution of bioreactor design and hepatocyte biology has resulted 25 
in bioreactors with considerable hope for ALF and ACLF treatment. These include: 26 
Extracorporeal Liver Assist Device™ (ELAD™); Academic Medical Centre Bioartificial Liver 27 
(AMC-BAL); and Spheroid Reservoir Bioartificial Liver (SRBAL). ELAD has entered human 28 
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clinical trials. SRBAL and the latest version of AMC-BAL  have shown efficacy in animal 1 
experiments, but data from human clinical trials are currently unavailable. 2 
 3 
A number of artificial ELSDs are in development that may either improve detoxification 4 
compared to current ELSDs or combine detoxification with techniques to attenuate liver 5 
injury. These include: Hepa Wash®; Li-Artificial Liver Support (49) and University College 6 
London-Liver Dialysis Device (UCL-LDD).  All three of these devices have shown efficacy in 7 
animal experiments, but data from human clinical trials are currently unavailable. 8 
 9 
Extracorporeal Liver Assist Device 10 
ELAD™ has been trialled in animal models of ALF and human liver failure patients since the 11 
1990s (50-52). Its key component is a quartet of hollow fibre dialysis cartridges containing 12 
HepG2/C3A cells, a human hepatoblastoma cell line, within the extra-fibre spaces 13 
(Supplementary Material Figure S4) . HepG2/C3A cells remain viable throughout the 14 
recommended 3-10 day treatment (53). HepG2/C3A cells demonstrate albumin synthesis 15 
and cytochrome P450 activity, but functionality is significantly less than primary hepatocytes 16 
with failure to detoxify ammonia via the urea cycle (48, 54). Early phase I pilot studies in 17 
limited numbers of human ALF patients have demonstrated safety, but no improvement in 18 
survival and biochemical and clinical parameters (51, 52). Preliminary results of a trial in 19 
patients with acute decompensation of chronic hepatitis B or C reported significant extension 20 
of 30 day transplant free survival and biochemical improvement (Table 3) (55). Clinical trials 21 
of ELAD™ in ACLF, ALF, severe acute alcoholic hepatitis and alcoholic-induced liver failure 22 
are currently ongoing (56). In a recent press release, the results of the large randomised trial 23 
of ELAD™ in alcohol-related ACLF patients were reported to be negative (57). The full report 24 
is awaited. 25 
 26 
Academic Medical Centre Bioartificial Liver 27 
 11 
 
The AMC-BAL has been in development since the 1990s (58). Key bioreactor features are: a 1 
non-woven matrix for 3-D hepatocyte cultures; spiralling of this 3-D matrix around oxygen 2 
carrying capillaries; and direct exposure of hepatocytes to patient plasma (Supplementary 3 
Material Figure S5). Primary hepatocyte viability has been reported to be 90% on day three. 4 
The first phase I clinical trial of AMC-BAL in man used a device containing primary porcine 5 
hepatocytes.  In this trial 12 ALF patients were treated for 4 to 35h: eleven were successfully 6 
bridged to liver transplantation and one recovered spontaneously. AMC-BAL treatment was 7 
associated with improvement in neurological and haemodynamic status in all patients; 8 
improvement in renal function in those with renal insufficiency and reduction in 9 
hyperbilirubinaemia and lactic acidosis (58). Porcine endogenous retrovirus DNA was found 10 
in patient plasma directly after treatment, but was undetectable thereafter.  Nevertheless 11 
clinical use of this device was restricted due to ethical, immunological and zoonotic 12 
concerns. 13 
 14 
Recently the HepaRG human hepatoma cell line has been cultured in the AMC-BAL instead 15 
of primary porcine hepatocytes. HepaRG cells approximate primary hepatocyte cultures 16 
more than any other human hepatocyte cell line (48). Culture within the AMC-BAL: 1) 17 
increased hepatic functionality with respect to ammonia elimination, the urea cycle and 18 
cytochrome P450 activity and 2) revealed lactate consumption, amino acid metabolism, drug 19 
metabolism and bile acid production similar to that of primary hepatocytes (59). In a rat ALF 20 
model, the HepaRG-AMC-BAL resulted in a 50% increase in survival and delay in 21 
progression of HE, kidney failure and hyperammonaemia (60). 22 
 23 
Spheroid Reservoir Bioartificial Liver (SRBAL) 24 
SRBAL has been in development since the early 2000s. Its key component is a bioreactor 25 
containing primary porcine hepatocytes in suspension, which when exposed to an oscillation 26 
frequency of 0.25Hz cluster into spheroids with stable cell viability (Supplementary Material 27 
Figure S6) (61, 62). Hepatocyte spheroids demonstrate good hepatocyte function in terms 28 
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of: phase I and phase II drug metabolism; ammonia conversion to urea via the urea cycle; 1 
and albumin synthesis (61). A trial using a pig ALF model has been reported (63).  Pigs were 2 
treated either with two 6-hour treatments (intermittent) or one 24 hour treatment 3 
(continuous). Both SRBAL treatments improved survival and reduced hyperammonaemia 4 
and continuous SRBAL reduced intracranial hypertension and brain water. 5 
 6 
Hepa Wash® 7 
Hepa Wash® is an artificial ELSD that detoxifies blood by albumin dialysis against a 2% 8 
albumin dialysate (64). The albumin dialysate is recirculated via a ‘Hepa Wash’ circuit, which 9 
contains two parallel conventional haemofilters, in which albumin bound toxins are released 10 
through exposure to an alkaline or acid environment and subsequently removed by filtration.  11 
This design aims to maintain clearances of protein bound toxins through the treatment 12 
period (64). This is contrary to MARS®, where a decline in clearance of protein bound toxins 13 
is seen throughout the recommended 7hr treatment (65).  14 
 15 
In a pig liver ischaemia ALF model, Hepa Wash® resulted in improvement in survival, 16 
cerebral perfusion pressure, haemodynamic status and kidney function. Moreover, Hepa 17 
Wash® resulted in reduction in azotaemia, hyperammonaemia, and blood nitrate/nitrite 18 
levels (64). Clinical trials in humans with ALF and ACLF were initiated in 2010, but have 19 
since been terminated for unknown reasons (NCT01079104, NCT01079091). 20 
 21 
Li-Artificial Liver Support (Li-ALS) 22 
Li-ALS is an artificial ELSD that combines a low-volume TPE (exchange of approximately 23 
2.5% body weight of plasma) circuit with a modified MARS secondary circuit, in which high-24 
flux hemofiltration replaces low-flux haemodialysis (49).  This approach seeks to benefit from 25 
the more comprehensive detoxification achieved by TPE compared to MARS, without need 26 
for a supply of exogenous fresh frozen plasma, as patient plasma is returned post-27 
detoxification to the patient. In a D-galactosamine pig model of ALF, Li-ALS resulted in an 28 
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improvement in survival compared to treatment with low-volume TPE alone and to treatment 1 
with the modified MARS circuit alone (49). 2 
 3 
University College London-Liver Dialysis Device (UCL-LDD) 4 
UCL-LDD is an artificial ELSD, in which blood is filtered across a high-cut off membrane 5 
(nominal cut-off of 60kDa) and then passed over a selective endotoxin adsorption 6 
membrane. Filtration across a high-cut off membrane results in albumin loss, which is 7 
replaced by HSA infusion (66). The resultant albumin exchange is proposed to correct 8 
irreversible loss of detoxifying function of albumin reported in liver failure. Reduction in 9 
endotoxaemia aims to reduce innate immune response, which worsens liver injury. Moreover 10 
high-cut off filters reduce circulating pro- and anti-inflammatory cytokines and correct 11 
immune dysfunction in septic patients with acute renal failure (67), so the same may apply to 12 
ALF. In a pig model of paracetamol-induced ALF, UCL-LDD improved survival and 13 
cardiovascular and respiratory function and reduced circulating dysfunctional albumin, 14 
endotoxaemia and immune system activation (66). 15 
 16 
CONCLUSION 17 
An ELSD that is able to bridge patients with liver failure either to recovery or to the state they 18 
were in, prior to the present deterioration, remains an unmet medical need. The main 19 
impediments to the development of an effective device can be thought of as being either 20 
patient related or device related. It is clear that once multiorgan failure is established, it is 21 
probably too late for an ELSD to be effective: in this situation the sole aim of ELSD treatment 22 
should be a bridge to transplant. Therefore, clinical trials need to include patients at risk of 23 
progression to multiorgan failure. The number of patients that will be required to attain 24 
adequate power will be high. It is also clear that the currently available devices show 25 
improvements in pathophysiological variables known to be associated with liver failure, but 26 
only one, TPE, has demonstrated survival benefit. The deficiencies of the currently available 27 
devices have inspired the newer devices, which are currently in clinical trials or due to enter 28 
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trials shortly. As ACLF has now been defined and the pathophysiology of both ALF and 1 
ACLF becomes clearer, it is very likely that an effective ELSD will emerge. Moreover further 2 
indications for ELSD may become evident. Indeed, new opportunity has arisen following the 3 
discovery of the new directly acting anti-viral drugs for Hepatitis C virus infection, which have 4 
been shown to reverse the severity of cirrhosis in many patients (68). One can envisage a 5 
situation whereby, Hepatitis C patients with decompensated cirrhosis are treated with ELSDs 6 
as out-patients for weeks and months, while the new directly acting anti-viral drugs take 7 
effect, negating the need for liver transplantation. 8 
 9 
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Table 1: Types of Liver Failure 1 
 Hyperacute/ 
Acute 
Sub acute ACLF 
underlying 
cirrhosis 
Decompensated 
cirrhosis 
Time from 
symptoms to 
failure 
Weeks Months Weeks Years 
Common 
aetiology 
Toxic ?Viral Variable Variable 
Precipitating 
event  
Liver injury Liver Injury Infection 
Alcohol 
Unknown 
Unknown 
Infection (others) 
Prognostic 
score 
Kings Kings CLIF C score MELD 
Potential for 
regeneration 
High Poor Unknown Poor 
 2 
Adapted from Jalan et al. Gastroenterology 2014 (1). 3 
  4 
 23 
 
Table 2: The CLIF Consortium organ failure score for the diagnosis of acute on 1 
chronic liver failure 2 
Organ System Score = 1 Score = 2 Score = 3 
Liver (mg/dl) Bilirubin < 6 6 ≤ Bilirubin ≤ 12 Bilirubin >12 
Kidney (mg/dl) Creatinine  <2.0 Creatinine ≥2.0 or 
<3.5 
Creatinine ≥3.5 or 
renal replacement 
Brain  
(West-Haven) 
Grade 0 Grade 1-2 Grade 3-4 
Coagulation INR < 2.0 2.0 ≤ INR < 2.5 INR ≥ 2.5 
Circulation MAP ≥70 mm/Hg MAP <70 mm/Hg Vasopressors 
Respiratory: 
PaO2/FiO2 
 or SpO2/FiO2  
>300 
>357  
≤300 - > 200 
>214- ≤357  
≤200 
≤214  
No ACLF: Patients with no organ failure; patients with single hepatic, coagulation, circulation 3 
or respiratory failure, serum creatinine <1.5 mg/dl and no HE; or patient with cerebral failure 4 
and serum creatinine <1.5 mg/dl. 5 
ACLF 1: Patients with renal failure or patients with other single organ failure with either 6 
serum creatinine ≥ 1.5 and < 2 mg/dl and/or HE grade 1-2.   7 
ACLF 2: Patients with 2 organ failures. 8 
ACLF 3: Patients with 3 or more organ failures. 9 
Adapted from Jalan et al. Journal of Hepatology 2014 (7) 10 
 11 
 12 
 24 
 
Table 3: Reported human randomised controlled clinical trials for ELSDs with survival as the primary outcome measure. 1 
Data from intention to treat (ITT) and per protocol (PP) analyses are included where reported separately. (ALF, acute liver failure; ACLF, acute-2 
on-chronic liver failure; n.s., no significant difference between groups; SMT, standard medical therapy; HVP, high-volume therapeutic plasma 3 
exchange) 4 
Liver support 
device 
Study name 
or identifier 
Type of trial Patient 
type 
Number of patients 
randomised 
(patients excluded 
after randomisation 
given in brackets) 
Primary outcome Secondary outcomes  
(only significant 
outcomes described) 
Safety profile 
MARS
®
 The RELIEF 
Trial (33) 
Multi-centre 
open 
randomised 
controlled 
trial 
ACLF Total=189 
MARS
® 
=95 
SMT=94 
(-ITT analysis: 5 
exclusions per group 
-PP analysis: 24 
MARS
®
 and 9 SMT 
exclusions) 
28-day ITT survival: MARS
®
, 61%; SMT, 
59% (n.s.). 
28-day PP survival: MARS
®
, 60%; SMT, 
59% (n.s.). 
  
At day 4, MARS
®
 
resulted in a significant 
reduction in serum 
creatinine, bilirubin and 
hepatic encephalopathy 
scores compared to 
SMT. 
Incidence of 
severe adverse 
events was 
similar in MARS
®
 
and SMT groups 
 25 
 
MARS
®
 The 
FULMAR 
Trial (34) 
Multi-centre 
open 
randomised 
controlled 
trial 
ALF Total=110 
MARS
® 
=57 
SMT=53 
(-ITT analysis: 4 
exclusions per group 
-PP analysis: 18 
MARS
®
 and 4 SMT 
exclusions) 
6-month ITT survival: MARS
®
, 85%; 
SMT, 76% (n.s.). 
6-month PP survival: MARS
®
, 82%; SMT, 
76% (n.s.). 
 Incidence of 
severe adverse 
events was 
similar in MARS
®
 
and SMT groups 
Prometheus
®
 The HELIOS 
trial (43) 
 
Multi-centre 
open 
randomised 
controlled 
trial 
ACLF Total=145 
Prometheus
®
=77 
SMT=68 
(-ITT analysis: 0 
exclusions 
-PP analysis: 22 
Prometheus
®
 and 14 
SMT exclusions) 
28-day ITT survival: Prometheus
®
, 66%; 
SMT, 63% (n.s.). 
28-day PP survival: Prometheus
®
, 71%; 
SMT, 67% (n.s.). 
90-day ITT survival: Prometheus
®
, 47%; 
SMT, 38% (n.s.). 
90-day PP survival: Prometheus
®
, 41%; 
SMT, 39% (n.s.). 
(Figure 2) 
At day 28, 
Prometheus
®
 resulted 
in a significant 
reduction in serum 
bilirubin compared to 
SMT. 
Incidence of 
severe adverse 
events was 
similar in 
Prometheus
®
 
and SMT groups 
 26 
 
High-volume 
therapeutic 
plasma 
exchange 
(HVP) 
ClinicalTrials
.gov number 
NCT002247
05 (47) 
Multi-centre 
open 
randomised 
controlled 
trial 
ALF Total=183 
HVP=92 
SMT=91 
(1 SMT excluded 
after randomisation) 
Survival to hospital discharge: HVP, 59%; 
SMT, 48% (P=0.008). 
(Figure 3) 
On day 1 to day 7, HVP 
resulted in significant 
reduction in 
international 
normalised ratio, 
bilirubin, ALT, SOFA-
score and CLIF-score. 
Incidence of 
severe adverse 
events was 
similar in HVP 
and SMT groups 
ELAD™ (55) 
 
Multi-centre 
open 
randomised 
controlled 
trial 
Chronic 
hepatitis 
B or C 
with 
acute 
decomp-
ensation 
Total=60  
ELAD™=40  
SMT=20 
(-ITT analysis: 0 
exclusions 
-PP analysis: 5 
ELAD™ and 1 SMT 
exclusions) 
30-day ITT transplant-free survival: 
ELAD™, 80%; SMT, 50% (P=0.03). 
30-day PP transplant-free survival: 
ELAD™, 86%; SMT, 47% (P=0.004). 
 ELAD™ was 
associated with 
significant 
thrombocytopeni
a, whilst SMT 
was not. 
 1 
 2 
 27 
 
FIGURE LEGENDS 1 
Figure 1: Survival data from the RELIEF trial.  2 
28-day survival for MARS® (light grey line) compared to standard medical therapy, SMT 3 
(dark grey line) with intention to treat analysis on the left and per protocol analysis on the 4 
right. Number of survivors at each time point is inserted into the graphs. See Table 3 for 5 
study details. (Reproduced with permission from Hepatology by John Wiley and Sons (33)) 6 
 7 
Figure 2: Survival data from the HELIOS trial. 8 
90-day intention to treat survival for Prometheus®, FPSA+SMT, compared to standard 9 
medical therapy, SMT. See Table 3 for study details. (Reproduced with permission from 10 
Gastroenterology by Elsevier (43)) 11 
 12 
Figure 3: Survival data from the high-volume plasma exchange trial. 13 
90-day intention to treat survival for high-volume plasma exchange, HVP, compared to 14 
standard medical therapy, SMT. See Table 3 for study details. (Reproduced with permission 15 
from Journal of Hepatology by Elsevier (47)) 16 
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